Gensight Biologics Aktie
| 0,25EUR | 0,01EUR | 2,30% |
WKN DE: A2ANGZ / ISIN: FR0013183985
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 25 | 38 | 46 | 16 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,18 | 0,14 | 0,06 | 0,08 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 43 | 53 | 23 | 6 | 5 |
| Summe Anlagevermögen | 4 | 3 | 3 | 3 | 5 |
| Summe Aktiva | 47 | 56 | 26 | 9 | 11 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 36 | 41 | 41 | 40 | 33 |
| Summe Eigenkapital | 11 | 16 | -15 | -31 | -27 |
| Summe Passiva | 47 | 56 | 26 | 9 | 11 |
Adresse
| 74, rue du Faubourg Saint-Antoine, 75012 Paris | |
| Telefon | +33 (1) 76-21-72-20 |
| Internet | http://www.gensight-biologics.com |
Management
|
Cédric Moreau
Director |
|
Elsy Boglioli Hofman
Independent Director |
|
Françoise de Craecker
Independent Director |
|
Ivan Tortet
Chief Financial Officer |
|
Julio J. Benedicto
Vice President-Strategic Marketing |
|
Laurence Rodriguez
Chief Executive Officer & Director |
|
Magali Gibou
Vice President-Regulatory & Quality |
|
Magali Taiel
Chief Medical Officer |
|
Marion Ghibaudo
Chief Technical Officer-Medical Device |
|
Maritza C. McIntyre
Independent Director |
|
Michael S. Wyzga
Chairman |
|
Scott Jeffers
Chief Technical Officer |
|
Simone Seiter
Independent Director |
|
Sissel Rodahl
Senior Vice President-Commercial Operations |
|
William Monteith
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.